Journal of nuclear medicine : official publication, Society of Nuclear Medicine

publication venue for

Quantitative study of radioiodinated metaiodobenzylguanidine uptake in children with neuroblastoma: correlation with tumor histopathology. 1989
¹⁸F-BMS-986229 PET to Assess Programmed-Death Ligand 1 Status in Gastroesophageal Cancer. 2024
Interrogating the Theranostic Capacity of a MUC16-Targeted Antibody for Ovarian Cancer. 2024
First-in-Human Evaluation of Site-Specifically Labeled ⁸⁹Zr-Pertuzumab in Patients with HER2-Positive Breast Cancer. 2024
²¹²Pb-Pretargeted Theranostics for Pancreatic Cancer. 2023
Antihormonal-Treatment Status Affects ⁶⁸Ga-PSMA-HBED-CC PET Biodistribution in Patients with Prostate Cancer.. 64. 2023
Correlation of SUV on Early Interim PET with Recurrence-Free Survival and Overall Survival in Primary Operable HER2-Positive Breast Cancer (the TBCRC026 Trial).. 64. 2023
Ambient Light Resistant Shortwave Infrared Fluorescence Imaging for Preclinical Tumor Delineation via the pH Low-Insertion Peptide Conjugated to Indocyanine Green.. 64. 2023
Immuno-PET Detects Antibody-Drug Potency on Coadministration with Statins.. 64. 2023
Efficacy of HER2-Targeted Intraperitoneal ²²⁵Ac α-Pretargeted Radioimmunotherapy for Small-Volume Ovarian Peritoneal Carcinomatosis. 2023
SNMMI Consensus Statement on Patient Selection and Appropriate Use of ¹⁷⁷Lu-PSMA-617 Radionuclide Therapy. 2023
Developing a novel patient reported outcomes measure for prostate cancer patients receiving radionuclide therapy. 2023
Noninvasive Assessment of Human Epidermal Growth Factor Receptor 2 (HER2) in Esophagogastric Cancer Using ⁸⁹Zr-Trastuzumab PET: A Pilot Study.. 64. 2022
Shortwave infrared detection of medical radioisotope Cerenkov luminescence. 2022
Molecular Imaging of Neuroendocrine Prostate Cancer by Targeting Delta-Like Ligand 3.. 63. 2022
Combined PARP1-targeted nuclear contrast and reflectance contrast enhances confocal microscopic detection of basal cell carcinoma. 2021
CD8-targeted PET Imaging of Tumor Infiltrating T cells in Patients with Cancer: A Phase I First-in-Human Study of ⁸⁹Zr-Df-IAB22M2C, a Radiolabeled anti-CD8 Minibody. 2021
Influence of Fc Modifications and IgG Subclass on Biodistribution of Humanized Antibodies Targeting L1CAM.. 63. 2021
Exploiting the MUC5AC Antigen for Noninvasive Identification of Pancreatic Cancer.. 62. 2021
Dual PET Imaging in Bronchial Neuroendocrine Neoplasms: The NETPET Score as a Prognostic Biomarker.. 62. 2021
Optoacoustic Imaging of Glucagon-like Peptide-1 Receptor with a Near-Infrared Exendin-4 Analog.. 62. 2020
Quo Vadis, Molecular Imaging?. 61. 2020
Head-to-Head Evaluation of ¹⁸F-FES and ¹⁸F-FDG PET/CT in Metastatic Invasive Lobular Breast Cancer.. 62. 2020
Oncology-Inspired Treatment Options for COVID-19.. 61. 2020
Immuno-PET Detects Changes in Multi-RTK Tumor Cell Expression Levels in Response to Targeted Kinase Inhibition.. 62. 2020
Synthesis of the PET Tracer ¹²⁴I-Trametinib for MAPK/ERK Kinase Distribution and Resistance Monitoring.. 61. 2020
First-in-Humans Trial of Dasatinib-Derivative Tracer for Tumor Kinase-Targeted PET.. 61. 2020
High-Resolution Depth-Encoding PET Detector Module with Prismatoid Light-Guide Array.. 61. 2020
Demarcation of Sepsis-Induced Peripheral and Central Acidosis with pH (Low) Insertion Cycle Peptide.. 61. 2020
PET/CT Imaging with an ¹⁸F-Labeled Galactodendritic Unit in a Galectin-1-Overexpressing Orthotopic Bladder Cancer Model.. 61. 2020
Positron Lymphography via Intracervical ¹⁸F-FDG Injection for Presurgical Lymphatic Mapping in Cervical and Endometrial Malignancies.. 61. 2020
Pharmacokinetic Assessment of ¹⁸F-(2S,4R)-4-Fluoroglutamine in Patients with Cancer.. 61. 2019
First-in-Humans Imaging with ⁸⁹Zr-Df-IAB22M2C Anti-CD8 Minibody in Patients with Solid Malignancies: Preliminary Pharmacokinetics, Biodistribution, and Lesion Targeting.. 61. 2019
An ⁸⁹Zr-HDL PET Tracer Monitors Response to a CSF1R Inhibitor.. 61. 2019
Biodistribution and Dosimetry of Intraventricularly Administered ¹²⁴I-Omburtamab in Patients with Metastatic Leptomeningeal Tumors.. 60. 2019
Multimodal ¹⁸F-AV-1451 and MRI Findings in Nonfluent Variant of Primary Progressive Aphasia: Possible Insights on Nodal Propagation of Tau Protein Across the Syntactic Network.. 61. 2019
PARaDIM: A PHITS-Based Monte Carlo Tool for Internal Dosimetry with Tetrahedral Mesh Computational Phantoms.. 60. 2019
A Fully Automatic Technique for Precise Localization and Quantification of Amyloid-β PET Scans.. 60. 2019
Temporal Modulation of HER2 Membrane Availability Increases Pertuzumab Uptake and Pretargeted Molecular Imaging of Gastric Tumors.. 60. 2019
Should Perfusion Scintigraphy Be Performed to Follow Patients with Acute Pulmonary Embolism? If So, When?. 60. 2019
Imaging Patients with Metastatic Castration-Resistant Prostate Cancer Using ⁸⁹Zr-DFO-MSTP2109A Anti-STEAP1 Antibody.. 60. 2019
Assessment of Simplified Methods for Quantification of ¹⁸F-FDHT Uptake in Patients with Metastatic Castration-Resistant Prostate Cancer.. 60. 2019
Albumin-Binding PSMA Ligands: Implications for Expanding the Therapeutic Window.. 60. 2018
¹⁸F-FDG PET/CT for Monitoring of Ipilimumab Therapy in Patients with Metastatic Melanoma.. 60. 2018
A Single Dose of ²²⁵Ac-RPS-074 Induces a Complete Tumor Response in an LNCaP Xenograft Model.. 60. 2018
Antibody with Infinite Affinity for In Vivo Tracking of Genetically Engineered Lymphocytes.. 59. 2018
Specific ¹⁸F-FDHT Accumulation in Human Prostate Cancer Xenograft Murine Models Is Facilitated by Prebinding to Sex Hormone-Binding Globulin.. 59. 2018
Development of a Dedicated Rebinner with Rigid Motion Correction for the mMR PET/MR Scanner, and Validation in a Large Cohort of ¹¹C-PIB Scans.. 59. 2018
Reproducibility and Repeatability of Semiquantitative ¹⁸F-Fluorodihydrotestosterone Uptake Metrics in Castration-Resistant Prostate Cancer Metastases: A Prospective Multicenter Study.. 59. 2018
PARP-1-Targeted Radiotherapy in Mouse Models of Glioblastoma.. 59. 2018
Immediate Postablation ¹⁸F-FDG Injection and Corresponding SUV Are Surrogate Biomarkers of Local Tumor Progression After Thermal Ablation of Colorectal Carcinoma Liver Metastases.. 59. 2018
Intraindividual Comparison of ^99mTc-Methylene Diphosphonate and Prostate-Specific Membrane Antigen Ligand ^99mTc-MIP-1427 in Patients with Osseous Metastasized Prostate Cancer.. 59. 2018
Head-to-Head Comparison of ¹¹C-PBR28 and ¹⁸F-GE180 for Quantification of the Translocator Protein in the Human Brain.. 59. 2018
First-in-Human Human Epidermal Growth Factor Receptor 2-Targeted Imaging Using ⁸⁹Zr-Pertuzumab PET/CT: Dosimetry and Clinical Application in Patients with Breast Cancer.. 59. 2017
Appropriate Use Criteria for Somatostatin Receptor PET Imaging in Neuroendocrine Tumors.. 59. 2017
Cerenkov-Activated Sticky Tag for In Vivo Fluorescence Imaging.. 59. 2017
Dynamic ¹⁸F-FDG PET Lymphography for In Vivo Identification of Lymph Node Metastases in Murine Melanoma.. 59. 2017
Noninvasive ⁸⁹Zr-Transferrin PET Shows Improved Tumor Targeting Compared with ¹⁸F-FDG PET in MYC-Overexpressing Human Triple-Negative Breast Cancer.. 59. 2017
Long-Half-Life ⁸⁹Zr-Labeled Radiotracers Can Guide Percutaneous Biopsy Within the PET/CT Suite Without Reinjection of Radiotracer.. 59. 2017
Biodistribution and Dosimetry of ¹⁸F-Meta-Fluorobenzylguanidine: A First-in-Human PET/CT Imaging Study of Patients with Neuroendocrine Malignancies.. 59. 2017
Curative Multicycle Radioimmunotherapy Monitored by Quantitative SPECT/CT-Based Theranostics, Using Bispecific Antibody Pretargeting Strategy in Colorectal Cancer.. 58. 2017
Pharmacokinetics, Biodistribution, and Radiation Dosimetry for ⁸⁹Zr-Trastuzumab in Patients with Esophagogastric Cancer.. 59. 2017
Dual-Target Binding Ligands with Modulated Pharmacokinetics for Endoradiotherapy of Prostate Cancer.. 58. 2017
Cerebrospinal Fluid Clearance in Alzheimer Disease Measured with Dynamic PET.. 58. 2017
Phase 2 Study of ^99mTc-Trofolastat SPECT/CT to Identify and Localize Prostate Cancer in Intermediate- and High-Risk Patients Undergoing Radical Prostatectomy and Extended Pelvic LN Dissection.. 58. 2017
⁸⁹Zr-DFO-AMG102 Immuno-PET to Determine Local Hepatocyte Growth Factor Protein Levels in Tumors for Enhanced Patient Selection.. 58. 2017
Pharmacokinetic Analysis of Dynamic ¹⁸F-Fluoromisonidazole PET Data in Non-Small Cell Lung Cancer.. 58. 2017
Prospective Clinical Trial of ¹⁸F-Fluciclovine PET/CT for Determining the Response to Neoadjuvant Therapy in Invasive Ductal and Invasive Lobular Breast Cancers.. 58. 2016
Prognostic Implications of Total Hemispheric Glucose Metabolism Ratio in Cerebrocerebellar Diaschisis.. 58. 2016
4-Dimensional MRI and Attenuation Map Generation in PET/MRI with 4-Dimensional PET-Derived Deformation Matrices: Study of Feasibility for Lung Cancer Applications.. 58. 2016
Comparison of Empiric Versus Whole-Body/-Blood Clearance Dosimetry-Based Approach to Radioactive Iodine Treatment in Patients with Metastases from Differentiated Thyroid Cancer.. 58. 2016
Evaluation of Castration-Resistant Prostate Cancer with Androgen Receptor-Axis Imaging.. 57. 2016
68Ga-DOTATATE PET/CT Interobserver Agreement for Neuroendocrine Tumor Assessment: Results of a Prospective Study on 50 Patients.. 58. 2016
Dual-Modality Imaging of Prostate Cancer with a Fluorescent and Radiogallium-Labeled Gastrin-Releasing Peptide Receptor Antagonist.. 58. 2016
First-in-Human Imaging with 89Zr-Df-IAB2M Anti-PSMA Minibody in Patients with Metastatic Prostate Cancer: Pharmacokinetics, Biodistribution, Dosimetry, and Lesion Uptake.. 57. 2016
A Preanalytic Validation Study of Automated Bone Scan Index: Effect on Accuracy and Reproducibility Due to the Procedural Variabilities in Bone Scan Image Acquisition.. 57. 2016
Repeatability of Quantitative 18F-NaF PET: A Multicenter Study.. 57. 2016
Selective Imaging of VEGFR-1 and VEGFR-2 Using 89Zr-Labeled Single-Chain VEGF Mutants.. 57. 2016
Remodeling the Vascular Microenvironment of Glioblastoma with α-Particles.. 57. 2016
Detection of HER2-Positive Metastases in Patients with HER2-Negative Primary Breast Cancer Using 89Zr-Trastuzumab PET/CT.. 57. 2016
Vascular Targeted Radioimmunotherapy for the Treatment of Glioblastoma.. 57. 2016
Comprehensive Quality Control of the ITG 68Ge/68Ga Generator and Synthesis of 68Ga-DOTATOC and 68Ga-PSMA-HBED-CC for Clinical Imaging.. 57. 2016
Modulation of Abnormal Metabolic Brain Networks by Experimental Therapies in a Nonhuman Primate Model of Parkinson Disease: An Application to Human Retinal Pigment Epithelial Cell Implantation.. 57. 2016
The Impact That Number of Analyzed Metastatic Breast Cancer Lesions Has on Response Assessment by 18F-FDG PET/CT Using PERCIST.. 57. 2016
Initial Results of a Prospective Clinical Trial of 18F-Fluciclovine PET/CT in Newly Diagnosed Invasive Ductal and Invasive Lobular Breast Cancers.. 57. 2016
18F-FDG PET/CT Is an Immediate Imaging Biomarker of Treatment Success After Liver Metastasis Ablation.. 57. 2016
Preclinical 89Zr Immuno-PET of High-Grade Serous Ovarian Cancer and Lymph Node Metastasis.. 57. 2016
Supraclavicular Brown Adipose Tissue 18F-FDG Uptake and Cardiovascular Disease.. 57. 2016
Arsenic Trioxide as a Radiation Sensitizer for 131I-Metaiodobenzylguanidine Therapy: Results of a Phase II Study.. 57. 2016
Prospective Study of 3'-Deoxy-3'-18F-Fluorothymidine PET for Early Interim Response Assessment in Advanced-Stage B-Cell Lymphoma.. 57. 2015
Optimizing Evaluation of Patients with Low-to-Intermediate-Risk Acute Chest Pain: A Randomized Study Comparing Stress Myocardial Perfusion Tomography Incorporating Stress-Only Imaging Versus Cardiac CT.. 57. 2015
Feasibility of 18F-Fluoromisonidazole Kinetic Modeling in Head and Neck Cancer Using Shortened Acquisition Times.. 57. 2015
Pretargeted Immuno-PET of Pancreatic Cancer: Overcoming Circulating Antigen and Internalized Antibody to Reduce Radiation Doses.. 57. 2015
Automated Differential Diagnosis of Early Parkinsonism Using Metabolic Brain Networks: A Validation Study.. 57. 2015
Analytic Validation of the Automated Bone Scan Index as an Imaging Biomarker to Standardize Quantitative Changes in Bone Scans of Patients with Metastatic Prostate Cancer.. 57. 2015
Mapping Radiation Injury and Recovery in Bone Marrow Using 18F-FLT PET/CT and USPIO MRI in a Rat Model.. 57. 2015
Comparison of 18F-FDG PET/CT for Systemic Staging of Newly Diagnosed Invasive Lobular Carcinoma Versus Invasive Ductal Carcinoma.. 56. 2015
PET Imaging of Tumor-Associated Macrophages with 89Zr-Labeled High-Density Lipoprotein Nanoparticles.. 56. 2015
Comparative Analysis of T Cell Imaging with Human Nuclear Reporter Genes.. 56. 2015
Encapsulation of α-Particle-Emitting 225Ac3+ Ions Within Carbon Nanotubes.. 56. 2015
Human Radiation Dosimetry for the N-Methyl-D-Aspartate Receptor Radioligand 11C-CNS5161.. 56. 2015
Reconstruction-Incorporated Respiratory Motion Correction in Clinical Simultaneous PET/MR Imaging for Oncology Applications.. 56. 2015
Summary of the UPICT Protocol for 18F-FDG PET/CT Imaging in Oncology Clinical Trials.. 56. 2015
Cerenkov Luminescence Imaging for Radiation Dose Calculation of a ⁹⁰Y-Labeled Gastrin-Releasing Peptide Receptor Antagonist.. 56. 2015
Correlation of BRAFV600E Mutation and Glucose Metabolism in Thyroid Cancer Patients: An ¹⁸F-FDG PET Study.. 56. 2015
Feasibility of in situ, high-resolution correlation of tracer uptake with histopathology by quantitative autoradiography of biopsy specimens obtained under 18F-FDG PET/CT guidance.. 56. 2015
PMPA for nephroprotection in PSMA-targeted radionuclide therapy of prostate cancer.. 56. 2015
Cortical laminar binding of PET amyloid and tau tracers in Alzheimer disease.. 56. 2015
TBCRC 008: early change in 18F-FDG uptake on PET predicts response to preoperative systemic therapy in human epidermal growth factor receptor 2-negative primary operable breast cancer.. 56. 2014
Annotating STEAP1 regulation in prostate cancer with 89Zr immuno-PET.. 55. 2014
99mTc-labeled small-molecule inhibitors of prostate-specific membrane antigen: pharmacokinetics and biodistribution studies in healthy subjects and patients with metastatic prostate cancer.. 55. 2014
A modular labeling strategy for in vivo PET and near-infrared fluorescence imaging of nanoparticle tumor targeting.. 55. 2014
MIRD pamphlet No. 25: MIRDcell V2.0 software tool for dosimetric analysis of biologic response of multicellular populations.. 55. 2014
Efficient 1-step radiolabeling of monoclonal antibodies to high specific activity with 225Ac for α-particle radioimmunotherapy of cancer.. 55. 2014
A tyrosine kinase inhibitor-based high-affinity PET radiopharmaceutical targets vascular endothelial growth factor receptor.. 55. 2014
Phase-1 clinical trial results of high-specific-activity carrier-free 123I-iobenguane.. 55. 2014
Radiopharmaceutical therapy of patients with metastasized melanoma with the melanin-binding benzamide 131I-BA52.. 55. 2013
Clinical Cerenkov luminescence imaging of (18)F-FDG.. 55. 2013
Applying PET to broaden the diagnostic utility of the clinically validated CA19.9 serum biomarker for oncology.. 54. 2013
Feasibility and predictability of perioperative PET and estrogen receptor ligand in patients with invasive breast cancer.. 54. 2013
99mTc-labeled small-molecule inhibitors of prostate-specific membrane antigen for molecular imaging of prostate cancer.. 54. 2013
A pretargeted PET imaging strategy based on bioorthogonal Diels-Alder click chemistry.. 54. 2013
The role of copper in disulfiram-induced toxicity and radiosensitization of cancer cells.. 54. 2013
Monitoring afatinib treatment in HER2-positive gastric cancer with 18F-FDG and 89Zr-trastuzumab PET.. 54. 2013
Hyperpolarized [1-13C]dehydroascorbate MR spectroscopy in a murine model of prostate cancer: comparison with 18F-FDG PET.. 54. 2013
Generation of 4-dimensional CT images based on 4-dimensional PET-derived motion fields.. 54. 2013
First-in-man evaluation of 2 high-affinity PSMA-avid small molecules for imaging prostate cancer.. 54. 2013
Imaging tumor burden in the brain with 89Zr-transferrin.. 54. 2012
A vaccinia virus encoding the human sodium iodide symporter facilitates long-term image monitoring of virotherapy and targeted radiotherapy of pancreatic cancer.. 53. 2012
Image-guided PO2 probe measurements correlated with parametric images derived from 18F-fluoromisonidazole small-animal PET data in rats.. 53. 2012
18F-FDG PET/CT metabolic tumor volume and total lesion glycolysis predict outcome in oropharyngeal squamous cell carcinoma.. 53. 2012
Positron lymphography: multimodal, high-resolution, dynamic mapping and resection of lymph nodes after intradermal injection of 18F-FDG.. 53. 2012
Dose escalation study of no-carrier-added 131I-metaiodobenzylguanidine for relapsed or refractory neuroblastoma: new approaches to neuroblastoma therapy consortium trial.. 53. 2012
Inhibition of poly(ADP-Ribose) polymerase enhances the toxicity of 131I-metaiodobenzylguanidine/topotecan combination therapy to cells and xenografts that express the noradrenaline transporter.. 53. 2012
Treadmill exercise inducing mild to moderate ischemia has no significant effect on skeletal muscle or cardiac 18F-FDG uptake and image quality on subsequent whole-body PET scan.. 53. 2012
Bone marrow dosimetry using 124I-PET.. 53. 2012
Novel mechanistic insights into arginine deiminase pharmacology suggest 18F-FDG is not suitable to evaluate clinical response in melanoma.. 53. 2012
124I-huA33 antibody uptake is driven by A33 antigen concentration in tissues from colorectal cancer patients imaged by immuno-PET.. 52. 2011
Practical approach for comparative analysis of multilesion molecular imaging using a semiautomated program for PET/CT.. 52. 2011
Targeting the internal epitope of prostate-specific membrane antigen with 89Zr-7E11 immuno-PET.. 52. 2011
(124)I-huA33 antibody PET of colorectal cancer.. 52. 2011
In vivo imaging of Bcr-Abl overexpressing tumors with a radiolabeled imatinib analog as an imaging surrogate for imatinib.. 52. 2011
123I-MIP-1072, a small-molecule inhibitor of prostate-specific membrane antigen, is effective at monitoring tumor response to taxane therapy.. 52. 2011
Components of a curriculum for molecular imaging scientists.. 52. 2011
Correlation of in vivo and in vitro measures of carbonic anhydrase IX antigen expression in renal masses using antibody 124I-cG250.. 52. 2011
Magnitude of enhanced permeability and retention effect in tumors with different phenotypes: 89Zr-albumin as a model system.. 52. 2011
Searching for alternatives to full kinetic analysis in 18F-FDG PET: an extension of the simplified kinetic analysis method.. 52. 2011
18F-fluromisonidazole PET imaging as a biomarker for the response to 5,6-dimethylxanthenone-4-acetic acid in colorectal xenograft tumors.. 52. 2011
Role of glutamine in cancer: therapeutic and imaging implications. 52:1005-1008. 2011
Imaging expression of the human somatostatin receptor subtype-2 reporter gene with 68Ga-DOTATOC.. 52. 2010
18F-FDG PET/CT for the prediction and detection of local recurrence after radiofrequency ablation of malignant lung lesions.. 51. 2010
Phase I trial of 90Y-DOTATOC therapy in children and young adults with refractory solid tumors that express somatostatin receptors.. 51. 2010
A new pyrimidine-specific reporter gene: a mutated human deoxycytidine kinase suitable for PET during treatment with acycloguanosine-based cytotoxic drugs.. 51. 2010
The effect of posttherapy 131I SPECT/CT on risk classification and management of patients with differentiated thyroid cancer.. 51. 2010
18F-FDG PET/CT findings and circulating tumor cell counts in the monitoring of systemic therapies for bone metastases from breast cancer.. 51. 2010
89Zr-DFO-J591 for immunoPET of prostate-specific membrane antigen expression in vivo.. 51. 2010
Correlation between glycolytic phenotype and tumor grade in soft-tissue sarcomas by 18F-FDG PET.. 51. 2010
Cerenkov luminescence imaging of medical isotopes.. 51. 2010
High 18F-FDG uptake in microscopic peritoneal tumors requires physiologic hypoxia.. 51. 2010
18F-FDG PET of locally invasive breast cancer and association of estrogen receptor status with standardized uptake value: microarray and immunohistochemical analysis.. 51. 2010
Pharmacokinetic assessment of the uptake of 16beta-18F-fluoro-5alpha-dihydrotestosterone (FDHT) in prostate tumors as measured by PET.. 51. 2010
(124)I-iodopyridopyrimidinone for PET of Abl kinase-expressing tumors in vivo.. 51. 2010
Dopamine cell implantation in Parkinson's disease: long-term clinical and (18)F-FDOPA PET outcomes.. 51. 2009
Pharmacokinetic analysis of hypoxia (18)F-fluoromisonidazole dynamic PET in head and neck cancer.. 51. 2009
Downregulation of 18F-FDG uptake in PET as an early pharmacodynamic effect in treatment of non-small cell lung cancer with the mTOR inhibitor everolimus.. 50. 2009
2-18F-Fluoropropionic acid as a PET imaging agent for prostate cancer.. 50. 2009
Salivary gland side effects commonly develop several weeks after initial radioactive iodine ablation.. 50. 2009
A pharmacokinetic model for radioimmunotherapy delivered through cerebrospinal fluid for the treatment of leptomeningeal metastases.. 50. 2009
11C-dihydrotetrabenazine PET of the pancreas in subjects with long-standing type 1 diabetes and in healthy controls.. 50. 2009
In vivo biodistribution, PET imaging, and tumor accumulation of 86Y- and 111In-antimindin/RG-1, engineered antibody fragments in LNCaP tumor-bearing nude mice.. 50. 2009
Retrospective study of 18F-FDG PET/CT in the diagnosis of inflammatory breast cancer: preliminary data.. 50. 2009
Sensitivity and specificity of perfusion scintigraphy combined with chest radiography for acute pulmonary embolism in PIOPED II.. 49. 2008
Comparison of 6-18F-fluorodopamine PET with 123I-metaiodobenzylguanidine and 111in-pentetreotide scintigraphy in localization of nonmetastatic and metastatic pheochromocytoma.. 49. 2008
An imaging comparison of 64Cu-ATSM and 60Cu-ATSM in cancer of the uterine cervix.. 49. 2008
Antibody mass escalation study in patients with castration-resistant prostate cancer using 111In-J591: lesion detectability and dosimetric projections for 90Y radioimmunotherapy.. 49. 2008
Monitoring the efficacy of adoptively transferred prostate cancer-targeted human T lymphocytes with PET and bioluminescence imaging.. 49. 2008
Synthesis and evaluation of a series of 99mTc(CO)3+ lisinopril complexes for in vivo imaging of angiotensin-converting enzyme expression.. 49. 2008
A new acycloguanosine-specific supermutant of herpes simplex virus type 1 thymidine kinase suitable for PET imaging and suicide gene therapy for potential use in patients treated with pyrimidine-based cytotoxic drugs.. 49. 2008
Recombinant human TSH-assisted radioactive iodine remnant ablation achieves short-term clinical recurrence rates similar to those of traditional thyroid hormone withdrawal.. 49. 2008
Clinical utility of 18F-FDG PET/CT in assessing the neck after concurrent chemoradiotherapy for Locoregional advanced head and neck cancer.. 49. 2008
Imaging of HSV-tk Reporter gene expression: comparison between [18F]FEAU, [18F]FFEAU, and other imaging probes.. 49. 2008
Dynamic small-animal PET imaging of tumor proliferation with 3'-deoxy-3'-18F-fluorothymidine in a genetically engineered mouse model of high-grade gliomas.. 49. 2008
Multicenter standardized 18F-FDG PET diagnosis of mild cognitive impairment, Alzheimer's disease, and other dementias.. 49. 2008
1-11C-acetate as a PET radiopharmaceutical for imaging fatty acid synthase expression in prostate cancer.. 49. 2008
Assessing tumor hypoxia in cervical cancer by PET with 60Cu-labeled diacetyl-bis(N4-methylthiosemicarbazone).. 49. 2008
Pulsed high-intensity focused ultrasound enhances uptake of radiolabeled monoclonal antibody to human epidermoid tumor in nude mice.. 49. 2008
Usefulness of standardized uptake values for distinguishing adrenal glands with pheochromocytoma from normal adrenal glands by use of 6-18F-fluorodopamine PET.. 48. 2007
123I-5-IA-85380 SPECT imaging of nicotinic acetylcholine receptor availability in nonsmokers: effects of sex and menstrual phase.. 48. 2007
Limitations of CT during PET/CT.. 48. 2007
The effects of carbidopa on uptake of 6-18F-Fluoro-L-DOPA in PET of pheochromocytoma and extraadrenal abdominal paraganglioma.. 48. 2007
Very low probability interpretation of V/Q lung scans in combination with low probability objective clinical assessment reliably excludes pulmonary embolism: data from PIOPED II.. 48. 2007
Tumor targeting with antibody-functionalized, radiolabeled carbon nanotubes.. 48. 2007
(18)F-FDG PET database of longitudinally confirmed healthy elderly individuals improves detection of mild cognitive impairment and Alzheimer's disease.. 48. 2007
Brown fat imaging with (18)F-6-fluorodopamine PET/CT, (18)F-FDG PET/CT, and (123)I-MIBG SPECT: a study of patients being evaluated for pheochromocytoma.. 48. 2007
Modulation of dopaminergic and glutamatergic brain function: PET studies on parkinsonian rats.. 48. 2007
18F-FDG PET scanning correlates with tissue markers of poor prognosis and predicts mortality for patients after liver resection for colorectal metastases.. 48. 2007
Deep-inspiration breath-hold PET/CT: clinical findings with a new technique for detection and characterization of thoracic lesions.. 48. 2007
Imaging hNET reporter gene expression with 124I-MIBG.. 48. 2007
Partial-volume correction in PET: validation of an iterative postreconstruction method with phantom and patient data.. 48. 2007
A human-derived reporter gene for noninvasive imaging in humans: mitochondrial thymidine kinase type 2.. 48. 2007
Diagnostic accuracy of 18F-FDG PET in restaging patients with medullary thyroid carcinoma and elevated calcitonin levels.. 48. 2007
Deep-inspiration breath-hold PET/CT of the thorax.. 48. 2007
Prediction of absorbed dose to normal organs in thyroid cancer patients treated with 131I by use of 124I PET and 3-dimensional internal dosimetry software.. 48. 2007
Synthesis and biologic evaluation of 64Cu-labeled rhenium-cyclized alpha-MSH peptide analog using a cross-bridged cyclam chelator.. 48. 2007
64Cu-azabicyclo[3.2.2]nonane thiosemicarbazone complexes: radiopharmaceuticals for PET of topoisomerase II expression in tumors.. 47. 2006
Hypometabolism exceeds atrophy in presymptomatic early-onset familial Alzheimer's disease.. 47. 2006
Bispecific antibody pretargeting PET (immunoPET) with an 124I-labeled hapten-peptide.. 47. 2006
Empiric radioactive iodine dosing regimens frequently exceed maximum tolerated activity levels in elderly patients with thyroid cancer.. 47. 2006
Yield of brain 18F-FDG PET in evaluating patients with potentially operable non-small cell lung cancer.. 47. 2006
Diagnostic accuracy and prognostic value of 18F-FDG PET in Hürthle cell thyroid cancer patients.. 47. 2006
Organ and fetal absorbed dose estimates from 99mTc-sulfur colloid lymphoscintigraphy and sentinel node localization in breast cancer patients.. 47. 2006
Tumor-specific in vivo transfection with HSV-1 thymidine kinase gene using a Sindbis viral vector as a basis for prodrug ganciclovir activation and PET.. 47. 2006
Effects of pegfilgrastim on normal biodistribution of 18F-FDG: preclinical and clinical studies.. 47. 2006
18F-FDG PET/CT for detecting nodal metastases in patients with oral cancer staged N0 by clinical examination and CT/MRI.. 47. 2006
Early tumor response to Hsp90 therapy using HER2 PET: comparison with 18F-FDG PET.. 47. 2006
Assessment of myocardial metabolism in diabetic rats using small-animal PET: a feasibility study.. 47. 2006
Assessment of myocardial blood flow using 15O-water and 1-11C-acetate in rats with small-animal PET.. 47. 2006
Minimally invasive method of determining blood input function from PET images in rodents.. 47. 2006
Pretargeted radioimmunotherapy with a single-chain antibody/streptavidin construct and radiolabeled DOTA-biotin: strategies for reduction of the renal dose.. 47. 2006
Evaluation of (76)Br-FBAU as a PET reporter probe for HSV1-tk gene expression imaging using mouse models of human glioma.. 46. 2005
Attenuation correction of PET images with respiration-averaged CT images in PET/CT.. 46. 2005
Association of vascular 18F-FDG uptake with vascular calcification.. 46. 2005
Pretargeted radioimmunotherapy of mesothelin-expressing cancer using a tetravalent single-chain Fv-streptavidin fusion protein.. 46. 2005
Prediction of myelotoxicity based on bone marrow radiation-absorbed dose: radioimmunotherapy studies using 90Y- and 177Lu-labeled J591 antibodies specific for prostate-specific membrane antigen.. 46. 2005
Pharmacokinetics and biodistribution of 111In- and 177Lu-labeled J591 antibody specific for prostate-specific membrane antigen: prediction of 90Y-J591 radiation dosimetry based on 111In or 177Lu?. 46. 2005
Monitoring antiproliferative responses to kinase inhibitor therapy in mice with 3'-deoxy-3'-18F-fluorothymidine PET.. 46. 2005
Biodistribution and blood metabolism of 1-11C-methyl-4-piperidinyl n-butyrate in humans: an imaging agent for in vivo assessment of butyrylcholinesterase activity with PET.. 45. 2004
PET-based radiation dosimetry in man of 18F-fluorodihydrotestosterone, a new radiotracer for imaging prostate cancer.. 45. 2004
Coexpression of herpesviral thymidine kinase reporter gene and VEGF gene for noninvasive monitoring of therapeutic gene transfer: an in vitro evaluation.. 45. 2004
Patient-specific dosimetry for 131I thyroid cancer therapy using 124I PET and 3-dimensional-internal dosimetry (3D-ID) software.. 45. 2004
Phase I clinical trial with fractionated radioimmunotherapy using 131I-labeled chimeric G250 in metastatic renal cancer.. 45. 2004
Simplified kinetic analysis of tumor 18F-FDG uptake: a dynamic approach.. 45. 2004
The CT motion quantitation of lung lesions and its impact on PET-measured SUVs.. 45. 2004
PET performance measurements for an LSO-based combined PET/CT scanner using the National Electrical Manufacturers Association NU 2-2001 standard.. 45. 2004
Single-chain Fv-streptavidin substantially improved therapeutic index in multistep targeting directed at disialoganglioside GD2.. 45. 2004
Clinical implications of different image reconstruction parameters for interpretation of whole-body PET studies in cancer patients.. 45. 2004
Functional interactions of the entorhinal cortex: an 18F-FDG PET study on normal aging and Alzheimer's disease.. 45. 2004
Tumor localization of 16beta-18F-fluoro-5alpha-dihydrotestosterone versus 18F-FDG in patients with progressive, metastatic prostate cancer.. 45. 2004
Engineered liposomes for potential alpha-particle therapy of metastatic cancer.. 45. 2004
Pharmacokinetics, dosimetry, and toxicity of the targetable atomic generator, 225Ac-HuM195, in nonhuman primates.. 45. 2004
124I-labeled engineered anti-CEA minibodies and diabodies allow high-contrast, antigen-specific small-animal PET imaging of xenografts in athymic mice.. 44. 2003
Assessment of treatment response by autoradiography with (14)C-aminocyclopentane carboxylic acid, (67)Ga-DTPA, and (18)F-FDG in a herpes simplex virus thymidine kinase/ganciclovir brain tumor model.. 44. 2003
Reduction of respiratory motion artifacts in PET imaging of lung cancer by respiratory correlated dynamic PET: methodology and comparison with respiratory gated PET.. 44. 2003
Pharmacokinetics and Biodistribution of (86)Y-Trastuzumab for (90)Y dosimetry in an ovarian carcinoma model: correlative MicroPET and MRI.. 44. 2003
Components of professional competence for nuclear medicine physicians.. 44. 2003
Dosimetry of the dopamine transporter radioligand 18F-FPCIT in human subjects.. 44. 2003
Murine S factors for liver, spleen, and kidney.. 44. 2003
Radiolabeled monoclonal antibodies specific to the extracellular domain of prostate-specific membrane antigen: preclinical studies in nude mice bearing LNCaP human prostate tumor.. 44. 2003
Patient-specific, 3-dimensional dosimetry in non-Hodgkin's lymphoma patients treated with 131I-anti-B1 antibody: assessment of tumor dose-response.. 44. 2003
90Y-DOTA-hLL2: an agent for radioimmunotherapy of non-Hodgkin's lymphoma.. 44. 2003
Retrospective analysis of sentinel node localization in multifocal, multicentric, palpable, or nonpalpable breast cancer.. 44. 2003
A retrospective review of the effectiveness of recombinant human TSH as a preparation for radioiodine thyroid remnant ablation.. 43. 2002
Delineation of hypoxia in canine myocardium using PET and copper(II)-diacetyl-bis(N(4)-methylthiosemicarbazone).. 43. 2002
Comparative analysis of striatal FDOPA uptake in Parkinson's disease: ratio method versus graphical approach.. 43. 2002
Comparison of radiolabeled nucleoside probes (FIAU, FHBG, and FHPG) for PET imaging of HSV1-tk gene expression.. 43. 2002
PET predicts prognosis after 1 cycle of chemotherapy in aggressive lymphoma and Hodgkin's disease.. 43. 2002
Effect of respiratory gating on quantifying PET images of lung cancer.. 43. 2002
Iodination of annexin V for imaging apoptosis.. 43. 2002
Mapping of local renal blood flow with PET and H(2)(15)O.. 43. 2002
Combined 18F-FDG and 11C-methionine PET scans in patients with newly progressive metastatic prostate cancer.. 43. 2002
Metabolic network abnormalities in early Huntington's disease: an [(18)F]FDG PET study.. 42. 2001
Comparative cellular catabolism and retention of astatine-, bismuth-, and lead-radiolabeled internalizing monoclonal antibody.. 42. 2001
Alendronate does not interfere with 99mTc-methylene diphosphonate bone scanning.. 42. 2001
Noise reduction in oncology FDG PET images by iterative reconstruction: a quantitative assessment.. 42. 2001
Effect of whole-body (18)F-FDG PET imaging on clinical staging and management of patients with malignant lymphoma.. 42. 2001
PET imaging of (86)Y-labeled anti-Lewis Y monoclonal antibodies in a nude mouse model: comparison between (86)Y and (111)In radiolabels.. 42. 2001
Relative therapeutic efficacy of (125)I- and (131)I-labeled monoclonal antibody A33 in a human colon cancer xenograft.. 42. 2001
Tumor uptake of copper-diacetyl-bis(N(4)-methylthiosemicarbazone): effect of changes in tissue oxygenation.. 42. 2001
Lymphoscintigraphy and sentinel node localization in breast cancer patients: a comparison between 1-day and 2-day protocols.. 42. 2001
64Cu-TETA-octreotide as a PET imaging agent for patients with neuroendocrine tumors.. 42. 2001
Hypoxia-Induced increase in FDG uptake in MCF7 cells.. 42. 2001
Parametric images of antibody pharmacokinetics in Bi213-HuM195 therapy of leukemia.. 42. 2001
Optimizing the sequence of combination therapy with radiolabeled antibodies and fractionated external beam.. 41. 2000
Parametric images of blood flow in oncology PET studies using [15O]water.. 41. 2000
123I-IPPA SPECT for the prediction of enhanced left ventricular function after coronary bypass graft surgery. Multicenter IPPA Viability Trial Investigators. 123I-iodophenylpentadecanoic acid.. 41. 2000
DNA cleavage by 111In-labeled oligodeoxyribonucleotides.. 41. 2000
Radioiodine uptake in thyroid remnants during therapy after tracer dosimetry.. 41. 2000
Pharmacokinetics of 111In- and 125I-labeled antiTac single-chain Fv recombinant immunotoxin.. 41. 2000
Registration of planar emission images with reprojected CT data.. 41. 2000
Evaluation of 11C-colchicine for PET imaging of multiple drug resistance.. 41. 2000
Single-dose versus fractionated radioimmunotherapy: model comparisons for uniform tumor dosimetry.. 41. 2000
Effects of insulinlike growth factor binding proteins on insulinlike growth factor-I biodistribution in tumor-bearing nude mice.. 41. 2000
Effect of mental stress on myocardial blood flow and vasomotion in patients with coronary artery disease.. 41. 2000
Gated myocardial perfusion tomography for the assessment of left ventricular function and volumes: comparison with echocardiography.. 40. 1999
Pharmacokinetics and dosimetry of an alpha-particle emitter labeled antibody: 213Bi-HuM195 (anti-CD33) in patients with leukemia.. 40. 1999
131I radioimmunotherapy and fractionated external beam radiotherapy: comparative effectiveness in a human tumor xenograft.. 40. 1999
Preparation of alpha-emitting 213Bi-labeled antibody constructs for clinical use.. 40. 1999
Methods to avoid adverse effect of circulating antigen on biodistribution of 125I-labeled antiTac dsFv: preinjection of intact antibody versus clearance of antigen with adivin-biotin system.. 40. 1999
Reproducibility of regional metabolic covariance patterns: comparison of four populations.. 40. 1999
Bremsstrahlung radiation exposure from pure beta-ray emitters.. 40. 1999
Favorable effects of glycolate conjugation on the biodistribution of humanized antiTac Fab fragment.. 40. 1999
Similarities and differences in 111In- and 90Y-labeled 1B4M-DTPA antiTac monoclonal antibody distribution.. 40. 1999
Alpha-emitting bismuth cyclohexylbenzyl DTPA constructs of recombinant humanized anti-CD33 antibodies: pharmacokinetics, bioactivity, toxicity and chemistry.. 40. 1999
Evaluation of 64Cu-ATSM in vitro and in vivo in a hypoxic tumor model.. 40. 1999
Thyroid cancer dosimetry using clearance fitting.. 40. 1999
Radiotherapy, toxicity and dosimetry of copper-64-TETA-octreotide in tumor-bearing rats.. 39. 1998
Dopamine transporter imaging with fluorine-18-FPCIT and PET.. 39. 1998
Dexamethasone treatment and plasma glucose levels: relevance for fluorine-18-fluorodeoxyglucose uptake measurements in gliomas.. 39. 1998
Evaluation of the in vivo biodistribution of yttrium-labeled isomers of CHX-DTPA-conjugated monoclonal antibodies.. 39. 1998
Pharmacokinetic model of iodine-131-G250 antibody in renal cell carcinoma patients.. 39. 1998
Prospective study of simultaneous orthoiodohippurate and diethylenetriaminepentaacetic acid captopril renography. The Einstein/Cornell Collaborative Hypertension Group.. 39. 1998
Quantitative bone metastases analysis based on image segmentation.. 38. 1997
Localization of radiolabeled chemotactic peptide at focal sites of Escherichia coli infection in rabbits: evidence for a receptor-specific mechanism.. 38. 1997
Effect of haloperidol dose on iodine-123-IBZM brain SPECT imaging in schizophrenic patients.. 38. 1997
Implementation and evaluation of patient-specific three-dimensional internal dosimetry.. 38. 1997
Technetium-99m labeling and biodistribution of anti-TAC disulfide-stabilized Fv fragment.. 38. 1997
Pre-clinical evaluation of technetium-99m platelet receptor-binding peptide.. 38. 1997
SPECT imaging of dopamine transporter sites in normal and MPTP-Treated rhesus monkeys.. 38. 1997
Bladder wall radiation dose in humans from fluorine-18-FDOPA.. 37. 1996
Comparative nigrostriatal dopaminergic imaging with iodine-123-beta CIT-FP/SPECT and fluorine-18-FDOPA/PET.. 37. 1996
Monitoring of neoadjuvant therapy response of soft-tissue and musculoskeletal sarcoma using fluorine-18-FDG PET.. 37. 1996
Quantitative imaging of iodine-124 with PET.. 37. 1996
Prevention of radiolysis of monoclonal antibody during labeling.. 37. 1996
Simultaneous perfusion tomography and radionuclide angiography during dobutamine stress.. 37. 1996
Cerebral SPECT imaging: effect on clinical management.. 37. 1996
Enhancement of radiation dose to the nucleus by vesicular internalization of iodine-125-labeled A33 monoclonal antibody.. 37. 1996
Preclinical evaluation of technetium-99m-labeled somatostatin receptor-binding peptides.. 37. 1996
Exercise renography in untreated subjects with essential hypertension.. 37. 1996
Bone marrow dosimetry: regional variability of marrow-localizing antibody.. 37. 1996
Pharmacokinetics and dosimetry of iodine-125-IUdR in the treatment of colorectal cancer metastatic to liver.. 37. 1996
Pilot clinical trial of 5-[125I]iodo-2'-deoxyuridine in the treatment of colorectal cancer metastatic to the liver.. 37. 1996
Technetium-99m-white blood cell-specific imaging agent developed from platelet factor 4 to detect infection.. 37. 1996
Clinical significance of striatal DOPA decarboxylase activity in Parkinson's disease.. 37. 1996
Combined FDOPA and 3OMFD PET studies in Parkinson's disease.. 37. 1996
Evaluation of carbon-14-colchicine biodistribution with whole-body quantitative autoradiography in colchicine-sensitive and -resistant xenografts.. 37. 1996
Myocardial technetium-99m-teboroxime activity in acute coronary artery occlusion and reperfusion: relation to myocardial blood flow and viability.. 36. 1995
Phase I radioimmunotherapy trial with iodine-131-CC49 in metastatic colon carcinoma.. 36. 1995
Assessment of disease severity in parkinsonism with fluorine-18-fluorodeoxyglucose and PET.. 36. 1995
Clinical validation of SPECT and CT/MRI image registration in radiolabeled monoclonal antibody studies of colorectal carcinoma.. 35. 1994
Effect of metabolism on retention of indium-111-labeled monoclonal antibody in liver and blood.. 35. 1994
Flare on bone scintigraphy following Taxol chemotherapy for metastatic breast cancer.. 35. 1994
Synthesis of fluorine-18-labeled biotin derivatives: biodistribution and infection localization.. 35. 1994
Imaging of brain tumor proliferative activity with iodine-131-iododeoxyuridine.. 35. 1994
The dose uptake ratio as an index of glucose metabolism: useful parameter or oversimplification?. 35. 1994
Image analysis for the study of radionuclide distribution in tissue sections.. 35. 1994
In vivo uptake of carbon-14-colchicine for identification of tumor multidrug resistance.. 35. 1994
Input functions for 6-[fluorine-18]fluorodopa quantitation in parkinsonism: comparative studies and clinical correlations.. 35. 1994
Evaluation of the serum stability and in vivo biodistribution of CHX-DTPA and other ligands for yttrium labeling of monoclonal antibodies.. 35. 1994
In vivo bioactivity and biodistribution of chemotactic peptide analogs in nonhuman primates.. 34. 1993
Technetium-99m-labeled chemotactic peptides: comparison with indium-111-labeled white blood cells for localizing acute bacterial infection in the rabbit.. 34. 1993
Localization of indium-111-immunoglobulin G, technetium-99m-immunoglobulin G and indium-111-labeled white blood cells at sites of acute bacterial infection in rabbits.. 34. 1993
Principal axes and surface fitting methods for three-dimensional image registration.. 34. 1993
Technetium-99m-labeled hydrazino nicotinamide derivatized chemotactic peptide analogs for imaging focal sites of bacterial infection.. 34. 1993
Internal dosimetry using data derived from autoradiographs.. 34. 1993
Lesion-by-lesion comparison of computerized tomography and indium-111-labeled monoclonal antibody C110 radioimmunoscintigraphy in colorectal carcinoma: a multicenter trial.. 34. 1993
Chemistry and biological behavior of samarium-153 and rhenium-186-labeled hydroxyapatite particles: potential radiopharmaceuticals for radiation synovectomy.. 34. 1993
Myocardial substrate utilization and left ventricular function in adriamycin cardiomyopathy.. 34. 1993
Three-dimensional dosimetry for radioimmunotherapy treatment planning.. 34. 1993
Assessing collateral cerebral perfusion with technetium-99m-HMPAO SPECT during temporary internal carotid artery occlusion.. 34. 1993
Metaiodobenzylguanidine: evaluation of its potential as a tracer for monitoring doxorubicin cardiomyopathy.. 34. 1993
Iododeoxyuridine uptake and retention as a measure of tumor growth.. 34. 1993
Ventilation-perfusion scintigraphy in the PIOPED study. Part I. Data collection and tabulation.. 34. 1993
Ventilation-perfusion scintigraphy in the PIOPED study. Part II. Evaluation of the scintigraphic criteria and interpretations.. 34. 1993
Modeling and dosimetry of monoclonal antibody M195 (anti-CD33) in acute myelogenous leukemia.. 34. 1993
Rhenium-186-labeled monoclonal antibodies for radioimmunotherapy: preparation and evaluation.. 34. 1993
c-erbB2 protein overexpression in breast cancer as a target for PET using iodine-124-labeled monoclonal antibodies.. 33. 1992
Gallium imaging in metastatic and recurrent soft-tissue sarcoma.. 33. 1992
Significance of increased lung thallium uptake during adenosine thallium-201 scintigraphy.. 33. 1992
In-vivo identification of tumor multidrug resistance with 3H-colchicine [corrected].. 33. 1992
Validation of gallium-67-citrate single-photon emission computed tomography in biopsy-confirmed residual Hodgkin's disease in the mediastinum.. 33. 1992
Radionuclide diagnosis of vertebral osteomyelitis: indium-111-leukocyte and technetium-99m-methylene diphosphonate bone scintigraphy.. 32. 1991
Estimates of radiation absorbed dose for intraperitoneally administered iodine-131 radiolabeled B72.3 monoclonal antibody in patients with peritoneal carcinomatoses.. 32. 1991
Nuclear exercise testing and the management of coronary artery disease.. 32. 1991
Radioimmunodetection of neuroblastoma with iodine-131-3F8: correlation with biopsy, iodine-131-metaiodobenzylguanidine and standard diagnostic modalities.. 32. 1991
Total-hip arthroplasty: periprosthetic indium-111-labeled leukocyte activity and complementary technetium-99m-sulfur colloid imaging in suspected infection.. 31. 1990
Quantitative in vivo measurements of tumor perfusion using rubidium-81 and positron emission tomography.. 31. 1990
Serial changes in myocardial perfusion using tomographic technetium-99m-hexakis-2-methoxy-2-methylpropyl-isonitrile imaging following reperfusion therapy of myocardial infarction.. 31. 1990
In vivo fate of monoclonal antibody B72.3 in patients with colorectal cancer.. 31. 1990
Association between number and sites of new bone scan abnormalities and presence of skeletal metastases in patients with breast cancer.. 31. 1990
Indium-111-labeled leukocyte scintigraphy in hemodialysis access-site infection.. 31. 1990
Immunoreactivity affects the biodistribution and tumor targeting of radiolabeled anti-P97 Fab fragment.. 31. 1990
Nonuniformity of tumor dose in radioimmunotherapy.. 31. 1990
Diagnosis of coronary artery disease by radionuclide angiography: effect of combining indices of left ventricular function.. 30. 1989
Effect of source strength and attenuation on dual photon absorptiometry.. 30. 1989
Comparison of CT, MR, and PET in Alzheimer's dementia and normal aging.. 30. 1989
Comparison of iron-59, indium-111, and gallium-69 transferrin as a macromolecular tracer of vascular permeability and the transferrin receptor.. 30. 1989
Reduction of background activities by introduction of a diester linkage between antibody and a chelate in radioimmunodetection of tumor.. 30. 1989
Value of blood-pool subtraction in cardiac indium-111-labeled platelet imaging.. 30. 1989
In vitro complex formation and biodistribution of mouse antitumor monoclonal antibody in cancer patients.. 30. 1989
Biodistribution, dosimetry, and clinical evaluation of technetium-99m ethyl cysteinate dimer in normal subjects and in patients with chronic cerebral infarction.. 30. 1989
Technetium-99m ECD: a new brain imaging agent: in vivo kinetics and biodistribution studies in normal human subjects.. 30. 1989
Bone SPECT in patients with persistent back pain after lumbar spine surgery.. 30. 1989
Differences in biodistribution of indium-111-and iodine-131-labeled B72.3 monoclonal antibodies in patients with colorectal cancer.. 30. 1989
An improved tungsten-178/tantalum-178 generator system for high volume clinical applications.. 29. 1988
Radiotracers for low density lipoprotein biodistribution studies in vivo: technetium-99m low density lipoprotein versus radioiodinated low density lipoprotein preparations.. 29. 1988
Radioimmunoscintigraphy of colon cancer with iodine-131-labeled B72.3 monoclonal antibody.. 29. 1988
The effect of energy window on cardiac ejection fraction.. 29. 1988
Metabolic imaging of human extremity musculoskeletal tumors by PET.. 29. 1988
Effect of antibody dose on the imaging and biodistribution of indium-111 9.2.27 anti-melanoma monoclonal antibody.. 29. 1988
Georg de Hevesy Nuclear Medicine Pioneer Award Citation--1986. Rosalyn S. Yalow and Solomon A. Berson.. 28. 1987
Targeting of ganglioside GD2 monoclonal antibody to neuroblastoma.. 28. 1987
Indium-111 T101 monoclonal antibody is superior to iodine-131 T101 in imaging of cutaneous T-cell lymphoma.. 28. 1987
Test-retest studies of cerebral glucose metabolism using fluorine-18 deoxyglucose: validation of method.. 28. 1987
Comparison of left ventricular diastolic function as determined by nuclear cardiac probe, radionuclide angiography, and contrast cineangiography.. 27. 1986
Indium-111 platelet kinetics in normal human subjects: tropolone versus oxine methods.. 27. 1986
Utilization of lung scans by clinicians.. 27. 1986
Thallium-201 scintigraphic quantitation of regional flow disparity and subsequent redistribution in dogs.. 27. 1986
Melanoma localization in nude mice with monoclonal Fab against p97.. 26. 1985
Accuracy and precision of regional multiharmonic Fourier analysis of gated blood-pool images.. 25. 1984
Radioimmunoscintigraphy of human colon cancer xenografts in mice with radioiodinated monoclonal antibody B72.3.. 25. 1984
A gamma camera for medical applications, using a multiwire proportional counter.. 25. 1984
Short-term thymidine uptake in normal and neoplastic tissues: studies for PET.. 25. 1984
Contrast agents and spectroscopic probes in NMR.. 25. 1984
High-level iodination of monoclonal antibody fragments for radiotherapy.. 25. 1984
Principles of imaging by nuclear magnetic resonance.. 25. 1984
Multinuclear NMR studies of naturally occurring nuclei.. 25. 1984
Principles of nuclear magnetic resonance.. 25. 1984
Optimum fourier filtering of cardiac data: a minimum-error method: concise communication.. 24. 1983
Increased accumulation of 2-deoxy-2-[18F]Fluoro-D-glucose in liver metastases from colon carcinoma.. 23. 1982
Planar imaging of positron-emitting radionuclides with a multicrystal camera.. 23. 1982
Radiochemical analysis of Tc-99m human serum albumin with high-pressure liquid chromatography: concise communication.. 23. 1982
Positron imaging feasibility studies. I: Characteristics of [3H]thymidine uptake in rodent and canine neoplasms: concise communication.. 22. 1981
Positron imaging feasibility studies. II: Characteristics of 2-deoxyglucose uptake in rodent and canine neoplasms: concise communication.. 22. 1981
Albumin microspheres labeled with Ga-67 by chelation: concise communication.. 22. 1981
The use of technetium-99m sulfur colloid as a marker for experimental venous thrombosis: concise communication.. 22. 1981
Radiogallium localization in tumors: blood binding and transport and the role of transferrin.. 21. 1980
Radionuclide cinepneumography: flow-volume imaging of the respiratory cycle.. 21. 1980
A transferrin-mediated uptake of gallium-67 by EMT-6 sarcoma. I. Studies in tissue culture.. 20. 1979
A transferrin-mediated uptake of gallium-67 by EMT-6 sarcoma. II. Studies in vivo (BALB/c mice): concise communication.. 20. 1979
Cardiac chamber imaging: a comparison of red blood cells labeled with Tc-99m in vitro and in vivo.. 19. 1978
The radionuclide ejection fraction: a comparison of three radionuclide techniques with contrast angiography.. 18. 1977
The incorporation of Ga-67 into the ferritin fraction of rabbit hepatocytes in vivo.. 18. 1977
Gallium-67 citrate imaging in Hodgkin's disease: final report of cooperative group.. 18. 1977
A simplified approach to radionuclide venography: concise communication.. 17. 1976
Toadfish serum as a binder for in vitro assay of vitamin B12.. 17. 1976
Simple radiometric techniques for rapid detection of herpes simplex virus type 1 in WI-38 cell culture.. 17. 1976
Possible enhancement of 67Ga-citrate imaging by iron dextran.. 17. 1976
Distribution and retention of 35S-sodium sulfate in man.. 17. 1976
Letter: Simple method for zero extrapolation in plasma volume determination.. 16. 1975
Radiometric detection of the metabolic activity of Mycobacterium tuberculosis.. 16. 1975
Radiometric identification of Streptococcus Group A in throat cultures.. 16. 1975
Analysis of liver scanning in a general hospital.. 16. 1975
A rapid automated system for measurement of antibody titers.. 15. 1974
Sterility testing of radiopharmaceuticals.. 15. 1974
Comparison of the metabolism of iron-labeled transferrin (Fe-TF) and indium-labeled transferrin (In-TF) by the erythropoietic marrow.. 15. 1974
An automated system for measurement of leukocyte metabolism.. 15. 1974
A preliminary study of 51 Cr-labeled platelets for evaluation of splenic sequestration in chronic lymphocytic leukemia.. 14. 1973
Interpretation of the 67 Ga photoscan.. 14. 1973
False-positive liver scan due to breast prosthesis.. 14. 1973
Image artifacts in tomographic gamma camera systems.. 14. 1973
The influence of previous lumbar puncture and pneumoencephalography on the incidence of unsuccessful radioisotope cisternography.. 12. 1971
Dimensions of the normal adult spleen scan and prediction of spleen weight.. 12. 1971
Distribution of the erythron and the RES in the bone marrow organ.. 8. 1967
Radiopharmacology of a simplifield technetium-99m-colloid preparation for photoscanning.. 7. 1966
George de Hevesy in America.. 61. 2019
A Conversation Between Michael Phelps and Jason Lewis.. 60. 2019
Reply: Cerebrospinal Fluid, Hyposmia, and Dementia in Alzheimer Disease: Insights from Dynamic PET and a Hypothesis.. 59. 2018
Reply: Comparison of Empiric Versus Dosimetry-Guided Radioiodine Therapy: The Devil Is in the Details.. 58. 2017
Molecular Imaging and Targeted Radionuclide Therapy of Prostate Cancer.. 57. 2016
Roundtable on the Future of Nuclear Medicine Training.. 56. 2015
Reply: Human Cerenkov imaging using 18F-FDG.. 55. 2014
Would patient selection based on both calcitonin blood level and doubling time improve 18F-FDG PET sensitivity in restaging of medullary thyroid cancer?. 48. 2007
On measuring hypoxia in individual tumors with radiolabeled agents.. 42. 2001
Thyroid stunning.. 42. 2001
Comparison of the clearance of technetium-99m MAG3 and iodine-131 OIH.. 29. 1988
Atropine clearance from human plasma.. 20. 1979
Guidelines for the clinical evaluation of radiopharmaceutical drugs.. 19. 1978
Effect of phenobarbital on liver uptake of Ga-67.. 19. 1978
Coming of age: recombinant human thyroid-stimulating hormone as a preparation for (131)i therapy in thyroid cancer. 2003
Reply: Potential Use of Radiolabeled Antibodies for Imaging and Treatment of COVID-19. 2021
3D-Printable Platform for High-Throughput Small-Animal Imaging. 2020
A new age for recombinant human thyroid-stimulating hormone? 2009
Failure of iodine-131 MIBG imaging in small cell lung carcinoma. 1987
Consensus recommendations for the use of 18F-FDG PET as an indicator of therapeutic response in patients in National Cancer Institute Trials. 2006
Technetium-99m-labeled chemotactic peptides: specific for imaging infection?. 38. 1997
Triumph over mischance: a role for nuclear medicine in gene therapy.. 38. 1997
Cerebral versus myocardial stress perfusion imaging: role of pharmacological intervention in the diagnostic assessment of flow reserve.. 35. 1994
PET studies in psychiatry: validity, accuracy and future.. 35. 1994
Technetium-99m-HMPAO retention and the role of glutathione: the debate continues.. 32. 1991
Receptors on tumors studied with radionuclide scintigraphy.. 32. 1991
Biologic characterization of melanoma tumors by antigen-specific targeting of radiolabeled anti-tumor antibodies.. 32. 1991
Optical Imaging of Ionizing Radiation from Clinical Sources. 2016
The growing impact of bioorthogonal click chemistry on the development of radiopharmaceuticals. 2013
Noninvasive molecular imaging using reporter genes. 2013
Myocardial perfusion imaging for preoperative risk stratification. 2011
PET monitoring of therapy response in head and neck squamous cell carcinoma. 2009
Radiopharmaceuticals in preclinical and clinical development for monitoring of therapy with PET. 2009
Nuclear imaging and minimally invasive surgery in the management of hyperparathyroidism. 2008
Screening for cancer with PET and PET/CT: potential and limitations. 2007
The promise of targeted {alpha}-particle therapy. 2005
Radiopharmaceutical therapy for palliation of bone pain from osseous metastases. 2004
Neuroblastoma: a disease requiring a multitude of imaging studies. 2004
PET in the assessment of therapy response in patients with carcinoma of the head and neck and of the esophagus. 2004
PET/CT in oncology: integration into clinical management of lymphoma, melanoma, and gastrointestinal malignancies. 2004
18F-FDG PET evaluation of the response to therapy for lymphoma and for breast, lung, and colorectal carcinoma. 2003
Radon update: facts concerning environmental radon: levels, mitigation strategies, dosimetry, effects and guidelines. SNM Committee on Radiobiological Effects of Ionizing Radiation. 1994
Radioimmunodetection in cancer identification. 1992
Positron emission tomography: clinical status in the United States in 1987. ACNP/SNM Task Force on Clinical PET. 1988
Monoclonal antibodies in nuclear medicine. 1985
Pretargeting: A Path Forward for Radioimmunotherapy. 2022
Glu-Ureido-Based Inhibitors of Prostate-Specific Membrane Antigen: Lessons Learned During the Development of a Novel Class of Low-Molecular-Weight Theranostic Radiotracers. 2017
Identification of Ligands and Translation to Clinical Applications. 2017
The Rise of PSMA Ligands for Diagnosis and Therapy of Prostate Cancer. 2016
Theranostic nanoparticles. 2014
PET of hypoxia: current and future perspectives. 2012
Circulating tumor cells and PET. 2011
SPECT in acute pulmonary embolism. 2009
A ticket to ride: peptide radiopharmaceuticals. 1993
Dosimetric aspects of radiolabeled antibodies for tumor therapy. 1986

VIVO Weill Cornell Medical College

Journal of nuclear medicine : official publication, Society of Nuclear Medicine Journal

Overview

publication venue for

Identity

ISO Abbreviation

Linking ISSN

International Standard Serial Number (ISSN)

Electronic International Standard Serial Number (EISSN)